Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Cihan Erol, Esra Zeynelgil, Mutlu Hizal, Aysegul Dumludag, Mert Erciyestepe, Ender Kalaci, Sedat Biter, Teoman Sakalar, Merve Keskinkılıc, Seda Kahraman, Selver Isik, Pinar Gursoy, Yasin Kutlu, Yakup Ergun, Ilknur Deliktas, Oguzhan Yildiz, Murat Araz, Sinem Akbas, Pervin Can Sanci, Kazim Uygun, Ziya Kalkan, Dogan Bayram, Dogan Uncu, Sila Oksuz, Nedim Turan, Ozturk Ates, Ahmet Bilici, Saadettin Kilickap, Ilhan Oztop, Serdar Karakaya, Semra Paydas, Ahmet Demirkazik, Nuri Karadurmus, Mehmet Ali Nahit Sendur

Open source

DOI: 10.1007/s12094-026-04494-3
Published: 2026-07-04
Container: Clinical and Translational Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12094-026-04494-3,
  title = {Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)},
  author = {Cihan Erol and Esra Zeynelgil and Mutlu Hizal and Aysegul Dumludag and Mert Erciyestepe and Ender Kalaci and Sedat Biter and Teoman Sakalar and Merve Keskinkılıc and Seda Kahraman and Selver Isik and Pinar Gursoy and Yasin Kutlu and Yakup Ergun and Ilknur Deliktas and Oguzhan Yildiz and Murat Araz and Sinem Akbas and Pervin Can Sanci and Kazim Uygun and Ziya Kalkan and Dogan Bayram and Dogan Uncu and Sila Oksuz and Nedim Turan and Ozturk Ates and Ahmet Bilici and Saadettin Kilickap and Ilhan Oztop and Serdar Karakaya and Semra Paydas and Ahmet Demirkazik and Nuri Karadurmus and Mehmet Ali Nahit Sendur},
  year = {2026},
  journal = {Clinical and Translational Oncology},
  doi = {10.1007/s12094-026-04494-3},
  url = {https://doi.org/10.1007/s12094-026-04494-3}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)
AU  - Cihan Erol
AU  - Esra Zeynelgil
AU  - Mutlu Hizal
AU  - Aysegul Dumludag
AU  - Mert Erciyestepe
AU  - Ender Kalaci
AU  - Sedat Biter
AU  - Teoman Sakalar
AU  - Merve Keskinkılıc
AU  - Seda Kahraman
AU  - Selver Isik
AU  - Pinar Gursoy
AU  - Yasin Kutlu
AU  - Yakup Ergun
AU  - Ilknur Deliktas
AU  - Oguzhan Yildiz
AU  - Murat Araz
AU  - Sinem Akbas
AU  - Pervin Can Sanci
AU  - Kazim Uygun
AU  - Ziya Kalkan
AU  - Dogan Bayram
AU  - Dogan Uncu
AU  - Sila Oksuz
AU  - Nedim Turan
AU  - Ozturk Ates
AU  - Ahmet Bilici
AU  - Saadettin Kilickap
AU  - Ilhan Oztop
AU  - Serdar Karakaya
AU  - Semra Paydas
AU  - Ahmet Demirkazik
AU  - Nuri Karadurmus
AU  - Mehmet Ali Nahit Sendur
PY  - 2026
JO  - Clinical and Translational Oncology
DO  - 10.1007/s12094-026-04494-3
UR  - https://doi.org/10.1007/s12094-026-04494-3
ER  -

APA

Erol, C., Zeynelgil, E., Hizal, M., Dumludag, A., Erciyestepe, M., Kalaci, E., Biter, S., Sakalar, T., Keskinkılıc, M., Kahraman, S., Isik, S., Gursoy, P., Kutlu, Y., Ergun, Y., Deliktas, I., Yildiz, O., Araz, M., Akbas, S., Sanci, P. C., Uygun, K., Kalkan, Z., Bayram, D., Uncu, D., Oksuz, S., Turan, N., Ates, O., Bilici, A., Kilickap, S., Oztop, I., Karakaya, S., Paydas, S., Demirkazik, A., Karadurmus, N., & Sendur, M. A. N. (2026). Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study). Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04494-3

Source records

crossref · retrieved 2026-09-25T23:21:46.984Z